Locations:
SearchPlease join our staff as we participate or present in the following oral and poster presentations at the 2018 ASCO Annual Meeting
8:12-8:24 a.m.
S406
ORAL ABSTRACT SESSION:
Prospective clinical evaluation of blood-based tumor
mutational burden (bTMB) as a predictive biomarker
for atezolizumab (atezo) in 1L non-small cell lung
cancer (NSCLC): Interim B-F1RST results
Abstract 12001
Vamsidhar Velcheti, MD – Presenter
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
Study of 401,576 patients reveals differences in cancer burdens as well as overall survival
Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy